Sarah B. Goldberg MD, MPHAssociate Professor of Medicine (Medical Oncology), Yale School of Medicine/Yale Cancer Center, New Haven, Connecticut
Dr. Sarah Goldberg is an Associate Professor of Medicine in the division of Medical Oncology at the Yale School of Medicine and Yale Cancer Center. She specializes in the treatment of thoracic malignancies. Her research interests include personalized medicine and immunotherapy for non-small cell lung cancer and identification of biomarkers that predict response to treatment.
DisclosuresDr. Sarah Goldberg reports receiving research funding from AstraZeneca and Boehringer Ingelheim, and consulting for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Genetech, Amgen, Spectrum, and Blueprint Medicine.
Recent Contributions to PracticeUpdate:
- High-Risk Clinicopathologic Features and Outcomes Among Patients Receiving Adjuvant Chemotherapy for Early-Stage Non-Small Cell Lung Cancer
- Erlotinib vs Etoposide/Cisplatin With Radiotherapy in Unresectable Stage III EGFR Mutation–Positive NSCLC
- 2020 Top Stories in Oncology: Osimertinib in Early-Stage EGFR-Mutant NSCLC
- Lorlatinib as First-Line Treatment for ALK-Positive Advanced Lung Cancer
- Sotorasib for KRAS G12C Mutated Advanced Non-Small Cell Lung Cancer
- Capmatinib in MET Exon 14–Mutated or MET-Amplified NSCLC
- Pembrolizumab for Non-Small Cell Lung Cancer Associated Brain Metastases
- Osimertinib in EGFR T790M-Positive NSCLC Patients With Brain Metastases or Leptomeningeal Disease Who Progressed on Prior EGFR TKI Therapy
- Osimertinib Improves Overall Survival in EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
- ASCO: Comparative Efficacy of Chemoimmunotherapy vs Immunotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer